查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602272

mRNA 平台市场：按 mRNA 类型、mRNA 分子、应用、适应症和最终用户划分 - 2025-2030 年全球预测

mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Unmodified mRNA), mRNA Molecule (Monocistronic mRNA, Polycistronic mRNA), Application, Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年mRNA平台市场估值为135.2亿美元，预计2024年将达到163.3亿美元，复合年增长率为21.44%，到2030年将达到527.1亿美元。

mRNA 平台是生物技术和医学领域的一个变革性领域，主要涉及传讯RNA(mRNA) 技术的开发及其在治疗和疫苗中的应用。最近 mRNA COVID-19 疫苗的快速开发和部署凸显了它们的需求，并证明了加速疫苗生产的能力。除了疫苗之外，mRNA的应用范围正在扩展到个人化医疗、蛋白质替代疗法以及癌症和遗传性疾病等疾病的治疗。最终用途行业主要包括从事研发和治疗开发的製药公司、生物技术公司和医疗保健提供者。市场成长的主要驱动力是技术进步、解决未满足的医疗需求的能力以及增加对生物技术的投资。新的商机包括探索 mRNA 的非传统应用，例如再生医学和慢性病管理，以及扩大 mRNA 在人类医学之外的使用案例，例如兽医应用。为了利用这些机会，相关人员应该投资于研究伙伴关係和创新，以降低生产成本并增强交付解决方案。

主要市场统计
基准年[2023] 135.2亿美元
预计年份 [2024] 163.3亿美元
预测年份 [2030] 527.1亿美元
复合年增长率（%） 21.44%

然而，该市场面临着监管障碍、高开发成本、储存和运输 mRNA 的后勤复杂性以及现有治疗方法的竞争等挑战。知识产权壁垒和供应链脆弱性也是主要限制因素。然而，技术创新的潜力是巨大的，特别是在提高 mRNA 製剂的稳定性、开发脂质奈米粒子等新型递送系统以及优化大规模製造技术方面。这些发展有可能重新定义疾病管理和治疗。市场高度活跃，特点是技术变化迅速、商业性兴趣高、研发活动广泛。为了实现永续成长，公司应专注于加速研究和简化监管流程的协作生态系统，并为基于 mRNA 的新创新提供更顺畅的市场路径，并与政策制定者合作。

市场动态：揭示快速发展的 mRNA 平台市场的关键市场洞察

供需的动态交互作用正在改变 mRNA 平台市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大疫苗开发以满足不断增长的全球卫生准备需求
    • 随着生物医学领域的进步，mRNA 疗法和疫苗的可用性增加生物技术突破将 mRNA 疗法和疫苗的速度和扩充性推向新的高度
    • 增加资金筹措以推动 mRNA 疗法和医疗保健进步的突破
    • 由于慢性病的增加，对 mRNA 治疗的需求不断增加
  • 市场限制因素
    • 高製造成本限制了基于 mRNA 的治疗方法的采用和扩充性
    • 监管障碍和漫长的核准流程减缓了 mRNA 平台的开发和市场进入
  • 市场机会
    • 透过整合 mRNA 平台进行精准治疗，转型个人化医疗
    • 扩大 mRNA 技术在疫苗以外的治疗领域的潜力
    • 透过与製药公司的强大合作，快速加速基于 mRNA 的治疗方法的开发和商业化
  • 市场挑战
    • 用于储存和分发基于 mRNA 的治疗药物的低温运输基础设施有限；
    • mRNA 疗法的接受度和广泛使用有潜在的安全性和免疫抗原性问题。

波特五力：驾驭 mRNA 平台市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 mRNA 平台市场的外部影响

外部宏观环境因素在塑造 mRNA 平台市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解mRNA平台市场的竞争状况

对 mRNA 平台市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵mRNA平台市场厂商绩效评估

FPNV 定位矩阵是评估 mRNA 平台市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製 mRNA 平台市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对 mRNA 平台市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疫苗开发不断进步，以满足全球卫生措施日益增长的需求
      • 随着生物医学领域的进步，mRNA 治疗和疫苗的可用性正在增加。

生物技术的进步使 mRNA 疗法和疫苗在速度和扩充性达到新的高度

      • 增加资金以加速 mRNA 治疗和医疗保健进步的突破
      • 随着慢性病的增加，对mRNA治疗的需求不断增加
    • 抑制因素
      • 高生产成本限制了基于 mRNA 的药物的采用和扩充性
      • 监管障碍和漫长的核准流程减缓了 mRNA 平台的开发和市场进入
    • 机会
      • 整合 mRNA 平台将个人化医疗转变为精准治疗
      • 扩大 mRNA 技术在疫苗以外的治疗领域的潜力
      • 与製药公司的强有力合作迅速加速了基于 mRNA 的治疗方法的开发和商业化
    • 任务
      • 用于储存和分发基于 mRNA 的疗法的低温运输基础设施有限
      • 接受和广泛使用 mRNA 疗法的潜在安全性和免疫抗原性问题
  • 市场区隔分析
    • mRNA类型：核苷修饰的mRNA能够平衡免疫反应的有效性并减少副作用，并提高稳定性。
    • mRNA分子：单顺反子mRNA是开发精准标靶治疗所必需的
    • 应用：透过新型 mRNA 平台快速有效生产疫苗的需求不断扩大
    • 适应症：全球癌症发生率正在上升
    • 最终用户：製药公司广泛参与 mRNA 平台的行销和许可
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章 mRNA 平台市场（依 mRNA 类型）

  • 核苷修饰的mRNA
  • 未修饰的mRNA

第 7 章 mRNA 分子的 mRNA 平台市场

  • 单顺反子mRNA
  • 多顺反子mRNA

第八章 mRNA 平台市场：依应用分类

  • 药物
  • 疫苗

第 9 章 mRNA 平台市场（按适应症）

  • 自体免疫疾病
  • 癌症
  • 感染疾病
  • 呼吸系统疾病

第 10 章 mRNA 平台市场：依最终用户划分

  • 医院/诊所
  • 製药公司
  • 研究/学术机构

第十一章美洲mRNA平台市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太mRNA平台市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲/中东/非洲mRNA平台市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Cipla 加强对 Esrys 的投资，以加速新兴市场基于 mRNA 的呼吸疗法
    • Arcturus Therapeutics 在欧洲大会上展示了吸入 mRNA 治疗囊肿纤维化的有希望的初步资料
    • 默克投资超过 3 亿欧元新建研究中心，致力于 mRNA 和抗体开发
    • CureVac 和 MD 安德森合作开发基于 mRNA 的癌症疫苗，以满足未满足的医疗需求
    • VBI Vaccines Inc. 在加拿大政府的支持下推动 mRNA 疫苗技术
    • Blackstone 承诺提供 7.5 亿美元支持 Moderna 流感疫苗的开发和商业化
    • Novo Holdings以165亿美元收购Catalent，并计划将战略地点出售给诺和诺德
    • TriLink BioTechnologies 与FUJIFILM Toyama Chemical 合作提高 mRNA 药物开发和製造的效率
    • Eslis 开始首次针对病毒引起的气喘的创新吸入 RNA 疗法的人体试验
    • Moderna 透过新的澳洲培养箱网路和疫苗生产设施来推进 mRNA 研究
    • 比尔及梅琳达盖兹基金会投资 4,000 万美元为低收入国家生产低成本 mRNA 疫苗
    • 默克和 Moderna 开始治疗进行性黑色素瘤的国际 3 期试验
    • Applied DNA Sciences 收购 Spindle Biotech 以加强 mRNA 生产，旨在提高产量并降低成本
    • Sensible Biotechnologies 与 Gingo Bioworks 结成策略伙伴关係，以彻底改变 mRNA 生产
  • 战略分析和建议
    • 辉瑞公司
    • 摩德纳公司
    • 赛诺菲公司
    • 易特瑞斯有限公司

公司名单

  • Acuitas Therapeutics Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • Beam Therapeutics Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CureVac NV
  • Daiichi Sankyo Company, Limited
  • Danaher Corporation
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • FUJIFILM Holdings Corporation
  • Gritstone bio, Inc.
  • In-Cell-Art
  • Merck KGaA
  • Moderna Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Regulus Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Tiba Biotech LLC
  • TriLink BioTechnologies by Maravai LifeSciences
  • Verve Therapeutics, Inc.
Product Code: MRR-374DB5A05ED7

The mRNA Platform Market was valued at USD 13.52 billion in 2023, expected to reach USD 16.33 billion in 2024, and is projected to grow at a CAGR of 21.44%, to USD 52.71 billion by 2030.

The mRNA platform is a transformative segment within biotechnology and pharmaceuticals, involving the development of messenger RNA (mRNA) technologies for applications primarily in therapeutics and vaccines. Its necessity has been underscored recently by the rapid development and deployment of mRNA COVID-19 vaccines, showcasing its ability to accelerate vaccine production. Beyond vaccines, mRNA's application scope extends to personalized medicine, protein replacement therapies, and treatment of diseases such as cancer and genetic disorders. End-use industries predominantly include pharmaceuticals, biotech firms, and healthcare providers engaged in research and therapeutic development. Market growth is primarily driven by technological advancements, the ability to address unmet medical needs, and increasing investment in biotech. Emerging opportunities include exploring mRNA for non-traditional uses like regenerative medicine and chronic disease management, and expanding mRNA use cases outside of human medicine, such as in veterinary applications. To capitalize on these opportunities, stakeholders should invest in research partnerships and technological innovations that reduce production costs and enhance delivery solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 13.52 billion
Estimated Year [2024] USD 16.33 billion
Forecast Year [2030] USD 52.71 billion
CAGR (%) 21.44%

However, the market faces challenges such as regulatory hurdles, high developmental costs, and logistical complexities in mRNA storage and transport, alongside competition from established therapeutic modalities. Intellectual property barriers and supply chain vulnerabilities also pose significant limitations. Nonetheless, the potential for innovation is immense, particularly in improving the stability of mRNA products, developing novel delivery systems (like lipid nanoparticles), and optimizing large-scale manufacturing techniques. These developments could redefine disease management and treatment modalities. The market is highly dynamic, characterized by rapid technological shifts, considerable commercial interest, and extensive R&D activities. For sustained growth, companies should focus on collaborative ecosystems that expedite research and streamline regulatory processes, and they should engage with policy makers to facilitate smoother pathways to market for new mRNA-based innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving mRNA Platform Market

The mRNA Platform Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing development of vaccines to meet the rising need for global health preparedness
    • Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability
    • Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
    • Growing need for mRNA therapy with the rising prevalence of chronic diseases
  • Market Restraints
    • High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
    • Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
  • Market Opportunities
    • Integration of mRNA platforms to transform personalized medicine with precision therapies
    • Growing potential of mRNA technology in non-vaccine therapeutic areas
    • Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
  • Market Challenges
    • Limited cold chain infrastructure for storing and distributing mRNA-based treatments
    • Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies

Porter's Five Forces: A Strategic Tool for Navigating the mRNA Platform Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the mRNA Platform Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the mRNA Platform Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the mRNA Platform Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the mRNA Platform Market

A detailed market share analysis in the mRNA Platform Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the mRNA Platform Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the mRNA Platform Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the mRNA Platform Market

A strategic analysis of the mRNA Platform Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Arcturus Therapeutics Holdings, Inc., Beam Therapeutics Inc., BioNTech SE, Catalent, Inc., CureVac N.V., Daiichi Sankyo Company, Limited, Danaher Corporation, eTheRNA Immunotherapies NV, Ethris GmbH, FUJIFILM Holdings Corporation, Gritstone bio, Inc., In-Cell-Art, Merck KGaA, Moderna Inc., Novo Nordisk A/S, Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi SA, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., Tiba Biotech LLC, TriLink BioTechnologies by Maravai LifeSciences, and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on mRNA Type, market is studied across Nucleoside-Modified mRNA and Unmodified mRNA.
  • Based on mRNA Molecule, market is studied across Monocistronic mRNA and Polycistronic mRNA.
  • Based on Application, market is studied across Drugs and Vaccines.
  • Based on Indication, market is studied across Autoimmune Diseases, Cancer, Infectious Diseases, and Respiratory Diseases.
  • Based on End-User, market is studied across Hospitals & Clinics, Pharmaceutical Companies, and Research & Academic Institutiions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing development of vaccines to meet the rising need for global health preparedness
      • 5.1.1.2. Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field

Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability

      • 5.1.1.3. Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
      • 5.1.1.4. Growing need for mRNA therapy with the rising prevalence of chronic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
      • 5.1.2.2. Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of mRNA platforms to transform personalized medicine with precision therapies
      • 5.1.3.2. Growing potential of mRNA technology in non-vaccine therapeutic areas
      • 5.1.3.3. Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited cold chain infrastructure for storing and distributing mRNA-based treatments
      • 5.1.4.2. Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
    • 5.2.2. mRNA Molecule: Requirement of monocistronic mRNA for the development of precise, targeted therapies
    • 5.2.3. Application: Expanding need for quick and effective production of vaccines through novel mRNA platforms
    • 5.2.4. Indication: Increasing prevalence of cancer cases worldwide
    • 5.2.5. End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. mRNA Platform Market, by mRNA Type

  • 6.1. Introduction
  • 6.2. Nucleoside-Modified mRNA
  • 6.3. Unmodified mRNA

7. mRNA Platform Market, by mRNA Molecule

  • 7.1. Introduction
  • 7.2. Monocistronic mRNA
  • 7.3. Polycistronic mRNA

8. mRNA Platform Market, by Application

  • 8.1. Introduction
  • 8.2. Drugs
  • 8.3. Vaccines

9. mRNA Platform Market, by Indication

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cancer
  • 9.4. Infectious Diseases
  • 9.5. Respiratory Diseases

10. mRNA Platform Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospitals & Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research & Academic Institutiions

11. Americas mRNA Platform Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific mRNA Platform Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa mRNA Platform Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Cipla Boosts Investment in Ethris to Accelerate mRNA-Based Respiratory Therapies for Emerging Markets
    • 14.3.2. Arcturus Therapeutics to Present Promising Early Data on Inhaled mRNA Treatment for Cystic Fibrosis at European Conference
    • 14.3.3. Merck Invests Over Euro 300 Million in New Research Center Focused on mRNA and Antibody Development
    • 14.3.4. CureVac and MD Anderson Collaborate on mRNA-Based Cancer Vaccines for Unmet Medical Needs
    • 14.3.5. VBI Vaccines Inc.'s Advancement in mRNA Vaccine Technology with Government of Canada Support
    • 14.3.6. Blackstone Commits USD 750 Million to Support Moderna's Influenza Vaccine Development and Commercialization
    • 14.3.7. Novo Holdings Acquires Catalent for USD 16.5 Billion, Plans Strategic Site Sales to Novo Nordisk
    • 14.3.8. TriLink BioTechnologies and FUJIFILM Toyama Chemical Forge Partnership to Enhance mRNA Drug Development and Manufacturing Efficiency
    • 14.3.9. Ethris Launches First Human Trial of Innovative Inhaled RNA Therapy for Virus-Induced Asthma
    • 14.3.10. Moderna Inc. Advances mRNA Research with New Australian Incubator Network and Vaccine Manufacturing Facility
    • 14.3.11. Bill & Melinda Gates Foundation Invests USD 40 Million in Affordable mRNA Vaccine Manufacturing for Low-Income Nations"
    • 14.3.12. Merck and Moderna Launch Global Phase 3 Trial for Advanced Melanoma Therapy
    • 14.3.13. Applied DNA Sciences Enhances mRNA Manufacturing with Spindle Biotech Acquisition, Aims to Improve Yields and Reduce Costs
    • 14.3.14. Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Pfizer Inc.
    • 14.4.2. Moderna, Inc.
    • 14.4.3. Sanofi SA
    • 14.4.4. Ethris GmbH

Companies Mentioned

  • 1. Acuitas Therapeutics Inc.
  • 2. Arcturus Therapeutics Holdings, Inc.
  • 3. Beam Therapeutics Inc.
  • 4. BioNTech SE
  • 5. Catalent, Inc.
  • 6. CureVac N.V.
  • 7. Daiichi Sankyo Company, Limited
  • 8. Danaher Corporation
  • 9. eTheRNA Immunotherapies NV
  • 10. Ethris GmbH
  • 11. FUJIFILM Holdings Corporation
  • 12. Gritstone bio, Inc.
  • 13. In-Cell-Art
  • 14. Merck KGaA
  • 15. Moderna Inc.
  • 16. Novo Nordisk A/S
  • 17. Pfizer Inc.
  • 18. Precision BioSciences, Inc.
  • 19. Regulus Therapeutics Inc.
  • 20. Sangamo Therapeutics, Inc.
  • 21. Sanofi SA
  • 22. Takara Bio Inc.
  • 23. Telesis Bio Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Tiba Biotech LLC
  • 26. TriLink BioTechnologies by Maravai LifeSciences
  • 27. Verve Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. MRNA PLATFORM MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA PLATFORM MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA PLATFORM MARKET DYNAMICS
  • TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY MONOCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY POLYCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023